BXP:LSE-Beximco Pharmaceuticals Limited (GBX)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | LSE

Last Closing Price

GBX 76.75

Change

0.00 (0.00)%

Market Cap

GBX 0.70B

Volume

1.28K

Avg Analyst Target

N/A

Avg User Target

GBX
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesic and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was founded in 1976 and is headquartered in Dhaka, Bangladesh. Address: 19 Dhanmondi R/A, Dhaka, Bangladesh, 1205

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-24 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HIK:LSE Hikma Pharmaceuticals PLC

N/A

GBX6.12B 20.11 9.28
INDV:LSE Indivior PLC

N/A

GBX1.10B 16.67 5.31
APH:LSE Alliance Pharma plc

N/A

GBX0.54B 66.67 17.98
BMK:LSE Benchmark Holdings plc

N/A

GBX0.39B N/A 23.77
AMYT:LSE Amryt Pharma plc

N/A

GBX0.30B N/A N/A
SAR:LSE Sareum Holdings plc

N/A

GBX0.24B N/A N/A
EAH:LSE ECO Animal Health Group plc

N/A

GBX0.24B 70.00 17.95
AGY:LSE Allergy Therapeutics plc

N/A

GBX0.17B 26.85 10.38
VLG:LSE Venture Life Group plc

N/A

GBX0.12B 37.20 15.38
DNL:LSE Diurnal Group plc

N/A

GBX0.11B N/A N/A

ETFs Containing BXP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.25% 17% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.25% 17% F 6% F
Trailing 12 Months  
Capital Gain 76.44% 79% C+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 76.44% 79% C+ 88% B+
Trailing 5 Years  
Capital Gain 153.72% 85% B 91% A-
Dividend Return 17.84% 100% A+ 70% C-
Total Return 171.56% 92% A- 89% B+
Average Annual (5 Year Horizon)  
Capital Gain 20.01% 57% F 78% C+
Dividend Return 2.46% 100% A+ 84% B
Total Return 22.46% 64% D 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 53.70% 57% F 26% F
Risk Adjusted Return 41.82% 86% B 58% F
Market Capitalization 0.70B 86% B 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.12 100% A+ 56% F
Price/Book Ratio 1.12 100% A+ 63% D
Price / Cash Flow Ratio 0.13 50% F 64% D
EV/EBITDA 0.11 100% A+ 99% A+
Management Effectiveness  
Return on Equity 13.62% 86% B 74% C
Return on Invested Capital 10.33% 86% B 78% C+
Return on Assets 7.75% 93% A 82% B-
Debt to Equity Ratio 4.44% 100% A+ 80% B-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.89 46% F 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.